[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571098":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":62,"collaborators":38,"id":64,"slug":38,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":38,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":38,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":47,"whyStopped":38,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trop2\u002FHER2-targeted immunoPET imaging","EXPERIMENTAL","Enrolled patients will undergo a Trop2\u002FHER2-targeted immunoPET\u002FCT scanning.",[13,14],"Drug: [18F]F-RESCA-RT4","Drug: [18F]F-RESCA-RB14",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","[18F]F-RESCA-RT4","Enrolled patients will receive 0.05-0.1mCi\u002Fkg of \\[18F\\]F-RESCA-RT4. ImmunoPET\u002FCT imaging will be acquired 1 hour after \\[18F\\]F-RESCA-RT4 injection.",[9],[22],"[18F]F-RT4",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"[18F]F-RESCA-RB14","Enrolled patients will receive 0.05-0.1mCi\u002Fkg of \\[18F\\]F-RESCA-RB14. ImmunoPET\u002FCT imaging will be acquired 1 hour after \\[18F\\]F-RESCA-RB14 injection.",[9],[28],"[18F]F-RB14",[30],{"name":31,"affiliation":32,"role":33},"Weijun Wei, Ph.D. & M.D.","Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","STUDY_CHAIR",[35,40],{"name":31,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","15000083153",null,"wwei@shsmu.edu.cn",{"name":41,"role":36,"phone":42,"phoneExt":38,"email":43},"Wenzhi Jia, Ph.D. & M.D.","18317076979","jwzdata@126.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","Shanghai Municipality","200127","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60,61],{"name":31,"role":36,"phone":37,"phoneExt":38,"email":39},{"name":41,"role":36,"phone":42,"phoneExt":38,"email":43},{"type":63,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100571098",false,"NCT06715826","Target-specific immunoPET Imaging of Breast Cancer","Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years old and of female gender；\n2. Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","FEMALE","18 Years","75 Years",{"count":74,"type":75},200,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE1","PHASE2","The aim of this study is to establish and optimize the Trop2\u002FHER2-targeted PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.",[82,83,84],"Breast Cancer","Breast Neoplasms","Breast Cancer Metastatic",[86,87,82,88],"Trop2","HER2","ImmunoPET","2026-01-25",{"date":91,"type":92},"2026-01-27","ACTUAL",{"date":94,"type":92},"2024-09-21",{"date":96,"type":75},"2026-11",{"name":5,"class":6},1]